Premium
Hepatocellular carcinoma in long‐term sustained virological responders following antiviral combination therapy for chronic hepatitis C
Author(s) -
Scherzer T.M.,
Reddy K. R.,
Wrba F.,
Hofer H.,
Staufer K.,
SteindlMunda P.,
Gangl A.,
Ferenci P.
Publication year - 2008
Publication title -
journal of viral hepatitis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.329
H-Index - 100
eISSN - 1365-2893
pISSN - 1352-0504
DOI - 10.1111/j.1365-2893.2008.01006.x
Subject(s) - hepatocellular carcinoma , medicine , gastroenterology , hepatitis c virus , antiviral therapy , hepatitis c , incidence (geometry) , chronic hepatitis , carcinoma , oncology , virus , immunology , physics , optics
Summary. Antiviral treatment results in a sustained virologic response (SVR) in 50–75% of patients with chronic hepatitis C. Long‐term follow up studies have observed ongoing SVR in the overwhelming majority of them. Thus chronic hepatitis C is considered ‘cured’ if an SVR is achieved. Consequently, it is expected that in sustained virologic responders long‐term complications of hepatatic C virus (HCV) related chronic liver disease including hepatocellular carcinoma are eliminated or have a decreased incidence. We report on five patients (three from Austria, two from USA) who developed hepatocellular carcinoma during follow up (3–6 years) after achieving SVR. During follow up and at diagnosis all were HCV‐RNA neg. None of the patients had other liver diseases. One patient presented with bilateral adrenal metastasis, the remaining four with large hepatic tumours. Three patients were noncirrhotic at the start of treatment at the time of tumour diagnosis. Successful antiviral treatment in HCV patients does not prevent development of hepatocellular carcinoma even in non‐cirrhotic livers. Long‐term follow up of patients with SVR is mandatory and should include surveillance for hepatocellular carcinoma.